CBF Cobra Bio-Man.

 

TIDMCBF 
 
RNS Number : 3115C 
Cobra Bio-Manufacturing PLC 
11 November 2009 
 

Cobra Biomanufacturing Plc 
 
 
("Cobra" or the "Company") 
 
 
Possible Offer 
 
 
The Board of Cobra announces that it is in discussions which may or may not lead 
to an offer being made for the Company. 
 
 
The talks still remain at a preliminary stage and it is therefore too early to 
say whether the talks will result in an offer for the Company or, in the event 
that one is made, on what terms. 
 
 
This statement is made without the agreement or the approval of the potential 
offeror. 
 
 
A further announcement will be made when appropriate. 
 
 
In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, Cobra 
confirms that it currently has in issue 44,339,170 ordinary shares of 1p each, 
(no shares are held in treasury) and admitted to trading on AIM, a market 
operated by the London Stock Exchange. 
 
 
The International Securities Identification Number for Cobra's ordinary shares 
is GB0031704835. 
 
 
For further information, please contact: 
+-----------------------------------------+------------------------------+ 
| Cobra Biomanufacturing Plc              |    Tel: +44 (0) 1782 714 181 | 
+-----------------------------------------+------------------------------+ 
| Danny Chapchal, Chairman                |                              | 
+-----------------------------------------+------------------------------+ 
| Simon Saxby, Chief Executive            |                              | 
+-----------------------------------------+------------------------------+ 
| Peter Coleman, CFO and Company          |                              | 
| Secretary                               |                              | 
+-----------------------------------------+------------------------------+ 
|                                         |                              | 
+-----------------------------------------+------------------------------+ 
| Buchanan Communications                 |    Tel: +44 (0) 207 466 5000 | 
+-----------------------------------------+------------------------------+ 
| Tim Anderson                            |                              | 
+-----------------------------------------+------------------------------+ 
|                                         |                              | 
+-----------------------------------------+------------------------------+ 
| Seymour Pierce Ltd                      |    Tel: +44 (0) 207 107 8000 | 
+-----------------------------------------+------------------------------+ 
| Chris Howard / Christopher Wren         |                              | 
+-----------------------------------------+------------------------------+ 
 
 
The Directors of the Company accept responsibility for the information contained 
in this announcement. To the best of the knowledge and belief of the Directors 
of the Company (who have taken all reasonable care to ensure that such is the 
case) the information contained in this announcement is in accordance with the 
facts and does not omit anything likely to impact the import of this 
announcement. 
 
 
Seymour Pierce Limited ("Seymour Pierce"), which is regulated in the United 
Kingdom by the Financial Services Authority, is acting for Cobra in relation to 
the matters described in this announcement and is not advising any other person, 
and accordingly will not be responsible to anyone other than Cobra for providing 
the protections afforded to customers of Seymour Pierce or for providing advice 
in relation to the matters described in this announcement. 
 
 
Dealing Disclosure Requirements 
 
 
Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any 
person is, or becomes, "interested" (directly or indirectly) in 1% or more of 
any class of "relevant securities" of Cobra, all "dealings" in any "relevant 
securities" of that company (including by means of an option in respect of, or a 
derivative referenced to, any such "relevant securities") must be publicly 
disclosed by no later than 3.30 pm (London time) on the London business day 
following the date of the relevant transaction. This requirement will continue 
until the date on which the offer becomes, or is declared, unconditional as to 
acceptances, lapses or is otherwise withdrawn or on which the "offer period" 
otherwise ends. If two or more persons act together pursuant to an agreement or 
understanding, whether formal or informal, to acquire an "interest" in "relevant 
securities" of Cobra, they will be deemed to be a single person for the purpose 
of Rule 8.3. 
 
 
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant 
securities" of Cobra by Cobra, or by any of its respective "associates", must be 
disclosed by no later than 12.00 noon (London time) on the London business day 
following the date of the relevant transaction. 
 
 
A disclosure table, giving details of the companies in whose "relevant 
securities" "dealings" should be disclosed, and the number of such securities in 
issue, can be found on the Takeover Panel's website at 
www.thetakeoverpanel.org.uk. 
 
 
"Interests in securities" arise, in summary, when a person has long economic 
exposure, whether conditional or absolute, to changes in the price of 
securities. In particular, a person will be treated as having an "interest" by 
virtue of the ownership or control of securities, or by virtue of any option in 
respect of, or derivative referenced to, securities. 
 
 
Terms in quotation marks are defined in the Code, which can also be found on the 
Panel's website. If you are in any doubt as to whether or not you are required 
to disclose a "dealing" under Rule 8, you should consult the Panel. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 OFDFFUFASSUSEDF 
 

Cobra Bio-manufacturing (LSE:CBF)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025

Cobra Bio-manufacturing (LSE:CBF)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025